Accent Microcell (ACCENTMIC)
Fast GrowerFairStock Score: 32/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹286.9 |
| Market Cap | ₹688.24 Cr |
| P/E Ratio | 24.26 |
| ROCE | 23.66% |
| ROE | —% |
| Dividend Yield | 0.29% |
| Profit Growth | 9.71% |
| Debt/Equity | — |
| Sales Growth | 10.58% |
| Promoter Holding | 55.47% |
| 52-Week Range | ₹253 — ₹731.7 |
| Sector | Pharmaceuticals & Biotechnology |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Whenever I look at a pharmaceutical business, I first ask what durable advantage protects its earnings. Accent Microcell has a return on capital employed of 23.66%, which is impressive, and a Piotroski score of 7 out of 9, which suggests the financial fabric is not frail. Promoter holding of 55.47% is another plus because it keeps management's money alongside mine. But a good checklist is not a moat, and moats are what make earnings predictable.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer